参考文献/References:
［1］Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022［J］.CA Cancer J Clin,2022,72(1):7-33.
［2］Sun D,Cao M,Li H,et al.Cancer burden and trends in China:a review and comparison with Japan and South Korea［J］.Chin J Cancer Res,2020,32(2):129-139.
［3］朱鑫哲,李浩,虞先濬,等.2021年胰腺癌研究及诊疗新进展［J］.中国癌症杂志,2022,32(1):1-12.
［4］Teague A,Lim KH,WangGillam A.Advanced pancreatic adenocarcinoma:a review of current treatment strategies and developing therapies［J］.Ther Adv Med Oncol,2015,7(2):68-84.
［5］马金凤,陈灵艳.运用柴胡桂枝干姜汤治疗胰腺癌的体会［J］.中西医结合心血管病电子杂志,2017,5(26):195-196.
［6］中华人民共和国卫生部.中国常见恶性肿瘤诊治规范［M］.北京：北京医科大学，中国协和大学联合出版社,1991.
［7］Edge SB，Compton CC.The American Joint Committee on Cancer:the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM［J］.Ann Surg Oncol，2010，17(6):1471-1474.
［8］国家中医药管理局.中华人民共和国中医药行业标准—中医病症诊断疗效标准（2012版）［S］.北京：中国医药科技出版社，2012：214-215.
［9］项金峰,施思,梁丁孔,等.2015年胰腺癌研究及诊疗前沿进展［J］.中国癌症杂志,2016,26(4):281.
［10］Millikan KW,Deziel DJ,Silverstein J C,et al.Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas［J］.Am Surg,1999,65(7):618-623.
［11］郑伟,聂青,康静波,等.立体定向放疗联合吉西他滨治疗胰腺癌的临床观察［J］.临床肿瘤学杂志,2011,16(11):995-1000.
［12］Opitz FV,Haeberle L,Daum A,et al.Tumor microenvironment in pancreatic intraepithelial neoplasia［J］.Cancers (Basel),2021,13(24):6188.
［13］Hayashi A,Hong J,Iacobuziodonahue CA.The pancreatic cancer genome revisited［J］.Nat Rev Gastroenterol Hepatol,2021,18(7):469-481.
［14］周晶晶,陆新良.胰腺癌生物靶向药物的研究进展［J］.肿瘤,2016,36(2):220-230.
［15］Conroy T,Desseigne F,Ychou M,et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer［J］.N Engl J Med,2011,364(19):1817-1825.
［16］中国临床肿瘤学会胰腺癌专家委员会.胰腺癌综合诊治中国专家共识(2014年版)［J］.临床肿瘤学杂志,2014,19(4):362-364.
［17］乐根明,朱燕,陈晨，等.化疗联合立体定向放射治疗局部晚期胰腺癌的疗效观察［J］.实用临床医药杂志,2017,21(21):118-119.
［18］Rojas LA,Balachandran VP.Scaling the immune incline in PDAC［J］.Nat Rev Gastroenterol Hepatol,2021,18(7):453-454.
［19］OHara M H,OReilly E M,Rosemarie M,et al.Abstract CT004:A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nabpaclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients［J］.Cancer Res,2019,79(13):3.?
［20］杨帆,郭晓钟.中药单体对胰腺癌抑制作用及机制研究进展［J］.实用中医药杂志,2017,33(3):331-333.
［21］王丽娟,路军章.中医药治疗胰腺癌的研究进展［J］.中华中医药杂志,2016,31(3):961-964.
［22］李陆军,陶永梅.柴胡桂枝干姜汤现代临床应用［J］.中医药学报,2015,43(3):140-143.
［23］孙静宜,周天,代岳雯,马炳亚,胡凯文.胡凯文运用柴胡桂枝干姜汤治疗恶性肿瘤寒热错杂证经验［J］.北京中医药,2020,39(5):411-413.
［24］刘渡舟.伤寒论十四讲［M］.天津:天津科学技术出版社,1982:107.
［25］张保伟.刘渡舟教授论柴胡桂枝干姜汤的内涵与应用［J］.中医药学刊,2002,20(1):9.
相似文献/References:
[1]关茜１ 焦俊?１ 叶子豪１ 王克穷２.益脾扶正方联合化疗治疗中晚期食管癌 ２１ 例[J].陕西中医药大学学报,2019,(01):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
Guan Qian Jiao Junzhe Ye Zihao Wang Keqiong.Clinical Analysis of Yipi Fuzheng Recipe combined with Chemotherapy in the Treatment of Advanced Esophageal Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2019,(01):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
[2]刘追星 杨洋陈光伟 方瑜.扶正抗癌方联合化疗对中晚期非小细胞肺癌患者外周血 CD4+?CD8+ 细胞影响的临床研究[J].陕西中医药大学学报,2020,(5):076.[doi:10.13424/j.cnki.jsctcm.2020.05.019]
[3]尹湘君 阮家钊 柴毅 季旭明.非小细胞肺癌化疗后温下方加减干预临床疗效研究[J].陕西中医药大学学报,2021,44(02):075.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
YIN Xiang - jun,RUAN Jia - zhao,CHAI Yi,et al.Study on The Clinical Effects of Modified Warming Purging Prescription intervention after Chemotherapy for Non – small Cell Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(01):075.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
[4]党明 翟鑫.胃癌术后化疗联合益气逐瘀汤治疗有效性研究[J].陕西中医药大学学报,2022,(06):128.[doi:10.13424/j.cnki.jsctcm.2022.06.025]